Rare condition

Rare bone disease

ORPHA:93419 ↗

Search all Rare bone disease trialsAlert me when a trial opens

studies recruiting now

checking live

studies registered in total

checking live

countries with a recruiting site

checking live

recruiting study posted to date

checking live

Recruiting trials

Fetching live from ClinicalTrials.gov. This condition is not yet in our weekly snapshot; live results only.

Keep watching

Get an email when a new Rare bone disease study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

NORD ↗GARD ↗Orphanet ORPHA:93419 ↗

A group of conditions, not a single diagnosis

Orphanet classifies “Rare bone disease” as a category that groups several related conditions. Trials are usually registered under the specific condition, so the figures above may undercount. Browse the conditions in this group or see the classification on Orphanet.

Treatments being studied

22 approved treatments and 2 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Eptotermin Alfa (Opgenra)Approved: Tiludronic Acid (Skelid)Approved: Burosumab (Crysvita)Approved: Technetium Tc 99m Medronate (Amerscan mdp kit)Approved: MenatetrenoneApproved: Neridronic AcidApproved: Pamidronic AcidApproved: Etidronic AcidApproved: Vosoritide (Voxzogo)Approved: Velaglucerase Alfa (Vpriv)Approved: Clodronic AcidApproved: Alendronic Acid (Binosto)Approved: IpriflavoneApproved: Ibandronic AcidApproved: Zoledronic Acid (Aclasta)Approved: Strontium Ranelate (Osseor)Approved: Dibotermin Alfa (Inductos)Approved: Denosumab (Jubbonti)Approved: Eliglustat Tartrate (Cerdelga)Approved: Aluminum Chlorohydrate (Hyperdrol)Approved: Risedronic AcidApproved: Romosozumab (Evenity)

Phase 2Mecasermin (Bio-fd&c igf1)

Phase 2Bafetinib

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).